argenx’s (ARGX) Market Perform Rating Reaffirmed at William Blair

William Blair reaffirmed their market perform rating on shares of argenx (NASDAQ:ARGX) in a report issued on Monday, RTT News reports.

Several other research firms have also weighed in on ARGX. Piper Sandler reaffirmed an overweight rating and set a $522.00 target price on shares of argenx in a report on Monday. Truist Financial lifted their price target on shares of argenx from $370.00 to $440.00 and gave the company a buy rating in a research note on Tuesday, March 5th. HC Wainwright reissued a buy rating and issued a $448.00 price target on shares of argenx in a research note on Friday. JMP Securities dropped their price target on shares of argenx from $471.00 to $468.00 and set a market outperform rating on the stock in a research note on Friday, May 10th. Finally, Wedbush reissued an outperform rating and issued a $521.00 price target on shares of argenx in a research note on Thursday, April 18th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average price target of $520.68.

argenx Trading Down 2.2 %

ARGX opened at $378.30 on Monday. argenx has a 12-month low of $327.73 and a 12-month high of $550.76. The firm has a market capitalization of $22.48 billion, a PE ratio of -66.84 and a beta of 0.65. The firm has a 50 day moving average of $375.08 and a two-hundred day moving average of $388.61.

argenx (NASDAQ:ARGX) last posted its earnings results on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The firm had revenue of $412.51 million for the quarter, compared to analysts’ expectations of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same period last year, the firm earned ($0.52) earnings per share. As a group, analysts predict that argenx will post -2.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ARGX. Parkside Financial Bank & Trust purchased a new position in shares of argenx during the 3rd quarter worth $28,000. GAMMA Investing LLC raised its holdings in argenx by 420.0% in the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock valued at $31,000 after buying an additional 63 shares during the period. FNY Investment Advisers LLC purchased a new stake in argenx in the 4th quarter valued at about $38,000. Mather Group LLC. purchased a new stake in argenx in the 1st quarter valued at about $38,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new stake in argenx during the fourth quarter worth about $60,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.